Prevalence and Antifungal Susceptibility of the Emerging Fungal Species, Candida nivariensis, Isolated in a Teaching Hospital in Poland

Publications

Share / Export Citation / Email / Print / Text size:

Polish Journal of Microbiology

Polish Society of Microbiologists

Subject: Microbiology

GET ALERTS

ISSN: 1733-1331
eISSN: 2544-4646

DESCRIPTION

0
Reader(s)
0
Visit(s)

Comment(s)
0
Share(s)

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue / page

Related articles

VOLUME 68 , ISSUE 4 (Jan 2019) > List of articles

Prevalence and Antifungal Susceptibility of the Emerging Fungal Species, Candida nivariensis, Isolated in a Teaching Hospital in Poland

MAGDALENA SIKORA / ROBERT KUTHAN * / KATARZYNA PISKORSKA-MALOLEPSZA / MARLENA GOLAS-PRADZYNSKA / DARIUSZ DOMAŃSKI / EWA AUGUSTYNOWICZ-KOPEĆ / EWA SWOBODA-KOPEC

Keywords : Candida glabrata complex, Candida nivariensis, emerging pathogen, resistance to azoles

Citation Information : Polish Journal of Microbiology. Volume 68, Issue 4, Pages 303-308, DOI: https://doi.org/10.33073/pjm-2019-032

License : (CC-BY-4.0)

Published Online: 03-September-2019

ARTICLE

ABSTRACT

Content not available Share

FIGURES & TABLES

REFERENCES

  1. Alcoba-Flórez J, Méndez-Alvarez S, Cano J, Guarro J, Pérez-Roth E, del Pilar Arévalo M. Phenotypic and molecular characterization of Candida nivariensis sp. nov., a possible new opportunistic fungus. J Clin Microbiol. 2005;43(8):4107–4111. https:/doi.org/10.1128/JCM.43.8.4107-4111.2005
    [PUBMED] [CROSSREF]
  2. Alexander BD, Johnson MD, Pfeiffer CD, Jiménez-Ortigosa C, Catania J, Booker R, Castanheira M, Messer SA, Perlin DS, Pfaller MA. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis. 2013;56(12):1724–1732. https:/doi.org/10.1093/cid/cit136
    [PUBMED] [CROSSREF]
  3. Angoulvant A, Guitard J, Hennequin C. Old and new pathogenic Nakaseomyces species: epidemiology, biology, identification, pathogenicity and antifungal resistance. FEMS Yeast Res. 2016;16(2):fov114.
    [PUBMED]
  4. Arendrup MC, Dzajic E, Jensen RH, Johansen HK, Kjaldgaard P, Knudsen JD, Kristensen L, Leitz C, Lemming LE, Nielsen L, et al. Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme. Clin Microbiol Infect. 2013;19(8):e343–e353. https:/doi.org/10.1111/1469-0691.12212
    [PUBMED] [CROSSREF]
  5. Bassetti M, Ansaldi F, Nicolini L, Malfatto E, Molinari MP, Mussap M, Rebesco B, Bobbio Pallavicini F, Icardi G, Viscoli C. Incidence of candidaemia and relationship with fluconazole use in an intensive care unit. J Antimicrob Chemother. 2009;64(3):625–629. https:/doi.org/10.1093/jac/dkp251
    [CROSSREF]
  6. Bishop JA, Chase N, Lee R, Kurtzman CP, Merz WG. Production of white colonies on CHROMagar Candida medium by members of the Candida glabrata clade and other species with overlapping phenotypic traits. J Clin Microbiol. 2008;46(10):3498–3500. https:/doi.org/10.1128/JCM.00982-08
    [PUBMED] [CROSSREF]
  7. Borman AM, Petch R, Linton CJ, Palmer MD, Bridge PD, Johnson EM. Candida nivariensis, an emerging pathogenic fungus with multidrug resistance to antifungal agents. J Clin Microbiol. 2008; 46(3):933–938. https:/doi.org/10.1128/JCM.02116-07
    [PUBMED] [CROSSREF]
  8. Chowdhary A, Randhawa HS, Khan ZU, Ahmad S, Juneja S, Sharma B, Roy P, Sundar G, Joseph L. First isolations in India of Candida nivariensis, a globally emerging opportunistic pathogen. Med Mycol. 2010;48(2):416–420. https:/doi.org/10.3109/13693780903114231
    [PUBMED] [CROSSREF]
  9. Cleary JD, Garcia-Effron G, Chapman SW, Perlin DS. Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. Antimicrob Agents Chemother. 2008;52(6):2263–2265. https:/doi.org/10.1128/AAC.01568-07
    [PUBMED] [CROSSREF]
  10. Cleveland AA, Harrison LH, Farley MM, Hollick R, Stein B, Chiller TM, Lockhart SR, Park BJ. Declining incidence of candidemia and the shifting epidemiology of Candida resistance in two US metropolitan areas, 2008–2013: results from population-based surveillance. PLoS One. 2015;10(3):e0120452. https:/doi.org/10.1371/journal.pone.0120452
    [PUBMED] [CROSSREF]
  11. CLSI. Reference method for broth dilution antifungal susceptibility testing of yeasts. Standard M27-A3. Wayne (USA): Clinical and Laboratory Standards Institute; 2008.
  12. Colombo AL, Garnica M, Aranha Camargo LF, Da Cunha CA, Bandeira AC, Borghi D, Campos T, Senna AL, Valias Didier ME, Dias VC, et al. Candida glabrata: an emerging pathogen in Brazilian tertiary care hospitals. Med Mycol. 2013;51(1):38–44. https:/doi.org/10.3109/13693786.2012.698024
    [PUBMED] [CROSSREF]
  13. EUCAST. Clinical breakpoints for fungi v 9.0 [Internet]. Basel (Switzerland): The European Committee on Antimicrobial Susceptibility Testing; [cited 2019 Feb 01]. 2018. Available from: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/AFST/Clinical_breakpoints/Antifungal_breakpoints_v_9.0_180212.pdf
  14. Falagas ME, Roussos N, Vardakas KZ. Relative frequency of albicans and the various non-albicans Candida spp. among candidemia isolates from inpatients in various parts of the world: a systematic review. Int J Infect Dis. 2010;14(11):e954–e966. https:/doi.org/10.1016/j.ijid.2010.04.006
    [PUBMED] [CROSSREF]
  15. Fujita S, Senda Y, Okusi T, Ota Y, Takada H, Yamada K, Kawano M. Catheter-related fungemia due to fluconazole-resistant Candida nivariensis. J Clin Microbiol. 2007;45(10):3459–3461. https:/doi.org/10.1128/JCM.00727-07
    [PUBMED] [CROSSREF]
  16. Garcia-Effron G, Park S, Perlin DS. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob Agents Chemother. 2009;53(1):112–122. https:/doi.org/10.1128/AAC.01162-08
    [PUBMED] [CROSSREF]
  17. Gołaś M, Netsvyetayeva I, Sikora M, Piskorska K, Sulik-Tyszka B, Swoboda-Kopeć E. Trends in antifungal susceptibility of Candida species – one year observation. Pol J Microbiol. 2014;63(2):217–222.
    [PUBMED]
  18. Guinea J. Global trends in the distribution of Candida species causing candidemia. Clin Microbiol Infect. 2014;20 Suppl 6:5–10. https:/doi.org/10.1111/1469-0691.12539
    [CROSSREF]
  19. Hou X, Xiao M, Chen SCA, Wang H, Yu SY, Fan X, Kong F, Xu YC. Identification and Antifungal Susceptibility Profiles of Candida nivariensis and Candida bracarensis in a Multi-Center Chinese Collection of Yeasts. Front Microbiol. 2017;8:5. https:/doi.org/10.3389/fmicb.2017.00005
    [PUBMED]
  20. Katiyar S, Pfaller M, Edlind T. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob Agents Chemother. 2006;50(8):2892–2894. https:/doi.org/10.1128/AAC.00349-06
    [PUBMED] [CROSSREF]
  21. Kurtzman C, Robnett C. Phylogenetic relationships among yeasts of the ‘Saccharomyces complex’ determined from multigene sequence analyses. FEMS Yeast Res. 2003;3(4):417–432. https:/doi.org/10.1016/S1567-1356(03)00012-6
    [PUBMED] [CROSSREF]
  22. Li J, Shan Y, Fan S, Liu X. Prevalence of Candida nivariensis and Candida bracarensis in vulvovaginal Candidiasis. Mycopathologia. 2014;178(3-4): 279–283. https:/doi.org/10.1007/s11046-014-9800-2
    [PUBMED] [CROSSREF]
  23. Lockhart SR, Iqbal N, Cleveland AA, Farley MM, Harrison LH, Bolden CB, Baughman W, Stein B, Hollick R, Park BJ, et al. Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011. J Clin Microbiol. 2012;50(11): 3435–3442. https:/doi.org/10.1128/JCM.01283-12
    [PUBMED] [CROSSREF]
  24. Lockhart SR, Messer SA, Gherna M, Bishop JA, Merz WG, Pfaller MA, Diekema DJ. Identification of Candida nivariensis and Candida bracarensis in a large global collection of Candida glabrata isolates: comparison to the literature. J Clin Microbiol. 2009; 47(4):1216–1217. https:/doi.org/10.1128/JCM.02315-08
    [PUBMED] [CROSSREF]
  25. Miranda-Zapico I, Eraso E, Hernández-Almaraz JL, López-Soria LM, Carrillo-Muñoz AJ, Hernández-Molina JM, Quindós G. Prevalence and antifungal susceptibility patterns of new cryptic species inside the species complexes Candida parapsilosis and Candida glabrata among blood isolates from a Spanish tertiary hospital. J Antimicrob Chemother. 2011;66(10):2315–2322. https:/doi.org/10.1093/jac/dkr298
    [PUBMED] [CROSSREF]
  26. Morales-López S, Dudiuk C, Vivot W, Szusz W, Córdoba SB, Garcia-Effron G. Phenotypic and molecular evaluation of echinocandin susceptibility of Candida glabrata, Candida bracarensis, and Candida nivariensis strains isolated during 30 years in Argentina. Antimicrob Agents Chemother. 2017;61(7):e00170-17. https:/doi.org/10.1128/AAC.00170-17
    [PUBMED] [CROSSREF]
  27. Panackal AA, Gribskov JL, Staab JF, Kirby KA, Rinaldi M, Marr KA. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J Clin Microbiol. 2006;44(5):1740–1743. https:/doi.org/10.1128/JCM.44.5.1740-1743.2006
    [PUBMED] [CROSSREF]
  28. Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. J Clin Microbiol. 2004;42(7):3142–3146. https:/doi.org/10.1128/JCM.42.7.3142-3146.2004
    [PUBMED] [CROSSREF]
  29. Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M. Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009). J Clin Microbiol. 2011;49(1):396–399. https:/doi.org/10.1128/JCM.01398-10
    [PUBMED] [CROSSREF]
  30. Quindós G. Epidemiology of candidaemia and invasive candidiasis. A changing face. Rev Iberoam Micol. 2014;31(1):42–48. https:/doi.org/10.1016/j.riam.2013.10.001
    [PUBMED] [CROSSREF]
  31. Rodrigues CF, Silva S, Henriques M. Candida glabrata: a review of its features and resistance. Eur J Clin Microbiol Infect Dis. 2014; 33(5):673–688. https:/doi.org/10.1007/s10096-013-2009-3
    [PUBMED] [CROSSREF]
  32. Sharma C, Wankhede S, Muralidhar S, Prakash A, Singh PK, Kathuria S, Kumar DA, Khan N, Randhawa HS, Meis JF, et al. Candida nivariensis as an etiologic agent of vulvovaginal candidiasis in a tertiary care hospital of New Delhi, India. Diagn Microbiol Infect Dis. 2013;76(1):46–50. https:/doi.org/10.1016/j.diagmicrobio.2013.02.023
    [CROSSREF]
  33. Silva S, Negri M, Henriques M, Oliveira R, Williams DW, Azeredo J. Candida glabrata, Candida parapsilosis and Candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance. FEMS Microbiol Rev. 2012;36(2):288–305. https:/doi.org/10.1111/j.1574-6976.2011.00278.x
    [PUBMED] [CROSSREF]
  34. Tamura NK, Negri MFN, Bonassoli LA, Svidzinski TIE. [Virulence factors for Candida spp. recovered from intravascular catheters and hospital workers hands] (in Portuguese). Rev Soc Bras Med Trop. 2007;40(1):91–93. https:/doi.org/10.1590/S0037-86822007000100021
    [PUBMED] [CROSSREF]
  35. Tapia GG, Razonable RR, Eckel-Passow JE, Lahr BD, Afessa B, Keegan MT, Catania J, Baddour LM. A scoring model of factors associated with Candida glabrata candidemia among critically ill patients. Mycoses. 2012;55(3):228–236. https:/doi.org/10.1111/j.1439-0507.2011.02069.x
    [PUBMED] [CROSSREF]
  36. Tay ST, Lotfalikhani A, Sabet NS, Ponnampalavanar S, Sulaiman S, Na SL, Ng KP. Occurrence and characterization of Candida nivariensis from a culture collection of Candida glabrata clinical isolates in Malaysia. Mycopathologia. 2014;178(3-4): 307–314. https:/doi.org/10.1007/s11046-014-9778-9
    [CROSSREF]
  37. Thompson GR 3rd, Wiederhold NP, Vallor AC, Villareal NC, Lewis JS 2nd, Patterson TF. Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob Agents Chemother. 2008;52(10):3783–3785. https:/doi.org/10.1128/AAC.00473-08
    [PUBMED] [CROSSREF]

EXTRA FILES

COMMENTS